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Abstract
The protein tyrosine phosphatase LYP, a key regulator of TCR signaling, presents a single nucleotide polymorphism, C1858T,
associated with several autoimmune diseases such as type I diabetes, rheumatoid arthritis, and lupus. This polymorphism
changes an R by a W in the P1 Pro rich motif of LYP, which binds to CSK SH3 domain, another negative regulator of TCR
signaling. Based on the analysis of the mouse homologue, Pep, it was proposed that LYP and CSK bind constitutively to
inhibit LCK and subsequently TCR signaling. The detailed study of LYP/CSK interaction, here presented, showed that LYP/
CSK interaction was inducible upon TCR stimulation, and involved LYP P1 and P2 motifs, and CSK SH3 and SH2 domains.
Abrogating LYP/CSK interaction did not preclude the regulation of TCR signaling by these proteins.
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Introduction
LYP (lymphoid tyrosine phosphatase), encoded by the human
gene PTPN22, is a classical protein tyrosine phosphatase (PTP)
included in the group of PEST (Pro, Glu, Ser, and Thr)
phosphatases [1], which also contains PTP-PEST and HSCF
phosphatases. They share a highly similar N-terminal PTP domain
and a Pro-rich motif (PRM) in the C-terminus called CTH (C-
terminal homology domain). LYP and PTP-PEST present others
PRMs, in addition to the CTH, In particular, LYP includes two
other PRM: P1 motif (aa 615–620), and P2 motif (aa 690–700).
Another characteristic to all the PEST phosphatases is the capacity
to bind CSK, the kinase that regulates negatively Src family
kinases (SFKs) [2].
LYP expression is restricted to hematopoietic cells. Studies on T
lymphocytes have implicated this phosphatase in the regulation of
TCR signaling pathways [3] where several proteins have been
proposed to be LYP substrates, for example vav, the f chain [4],
Cbl [5] and the kinases LCK, Fyn and Zap-70 [4,6]. Among these
proteins, the best characterized substrate of LYP is LCK, a SFK
(Src family kinase) critical for T-cell development and activation.
LYP dephosphorylates LCK Tyr394, the positive regulatory Tyr
placed in its activation loop [4]. Another critical residue for LCK
activity is the C-terminal Tyr505 that, when is phosphorylated by
CSK, interacts intramolecularly with the SH2 domain and favors
a closed and inactive conformation of LCK. It has been proposed
that the concerted action of the tandem formed by Pep and CSK
inactivates LCK [6,7,8].
The description in LYP of a single nucleotide polymorphism
(SNP) [9,10] associated to several autoimmune diseases such as
type 1 diabetes, systemic lupus erytematosus and rheumatoid
arthritis [11] indicates that this phosphatase plays a critical role in
the regulation of the immune response. This SNP, C1858T,
changes into a Trp the Arg620 present in the P1 PRM that binds
to CSK SH3 domain [9,12]. Based on data obtained in T
lymphocytes, LYPW has been proposed to be a gain-of-function
variant with increased phosphatase activity that reduces early T-
cell signaling parameters such as Ca2+ mobilization and LCK
phosphorylation [13]. Nevertheless, it is not fully clear how these
changes in early signaling affect T cell physiology. A recent work
has proposed that a reduced interaction with CSK leads to a lower
tyrosine phosphorylation of LYP in a negative regulatory site,
responsible for the increase in the activity of LYP [14]. Although
the gain-of-function phenotype has received support from several
studies, there is no agreement on this point; and recent reports
have claimed that LYPW is a loss of function variant [15,16].
Furthermore, knockout mice deficient in Pep phosphatase did not
develop any autoimmune disease [17], despite augmented LCK
activity in re-stimulated T-lymphocytes and an increase in the
number of germinal centers.
Current knowledge about LYP/CSK binding is mainly based
on the study of Csk interaction with Pep [6,8,12]. However, no
detailed study has been yet reported on the association of LYP
with CSK to determine the validity of this model in human cells,
which is relevant to the pathogenesis of autoimmune diseases.
Therefore, to determine how the R620W polymorphism modifies
the function of this complex and contributes to the induction of
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autoimmunity, in this work we have analyzed LYP/CSK in-
teraction and its relevance for TCR signaling.
Materials and Methods
Antibodies and Reagents
Tissue culture reagents were from Lonza (Verviers, Belgium).
The anti-hemagglutinin (HA) mAb was from Covance (Berkely,
CA, USA). The anti-LCK mouse Ab (3A5), anti-GST Ab, anti-
myc Ab (9E10), anti-Erk2 Ab (C154), anti-Fyn Ab (6A406) and
anti-CSK rabbit polyclonal Ab (C-20) were from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA). The anti-CD3
(UCHT1), anti-CD28 (clone CD28.2), anti-Abl and anti-CSK
mouse Ab were from BD Pharmingen (Franklin Lakes, NJ, USA).
The anti-phosphotyrosine 4G10 mAb was from Millipore (Bill-
erica, MA, USA).The anti-LYP goat polyclonal Ab was from R&D
Systems, Inc. (Minneapolis, MN, USA). The anti-phospho-p38 Ab
was from Cell Signaling Technology Inc., (Beverly, MA,
USA).The anti-phospho-Erk Ab was from Promega (Fitchburg,
WI, USA).
Plasmids and Mutagenesis
Standard molecular biology techniques were used to generate
the different constructions used in this study. Site-directed
mutagenesis was done with the QuickChange Mutagenesis Kit
(Agilent-Stratagene, CA, USA) following the manufacturer in-
structions. All constructions and mutations were verified by
nucleotide sequencing.
Cell Culture and Transfections
HEK293 were maintained at 37uC in Dulbecco’s modified
Eagle’s medium supplemented with 10% FBS, 2 mM L-gluta-
mine, 100 U/ml penicillin G, and 100 mg/ml streptomycin.
Transient transfection of HEK293 cells was carried out using
the calcium phosphate precipitation method [18]. JCam1.6, P116
and Jurkat T leukemia cells were kept at logarithmic growth in
RPMI 1640 medium supplemented with 10% FBS, 2 mM L-
glutamine, 1 mM sodium pyruvate, non essential aa, 100 U/ml
penicillin G, and 100 mg/ml streptomycin. Transfection of Jurkat
T cells was performed by electroporation as described previously
[19]. PBLs were isolated from buffy coats of healthy donors
obtained from the regional blood bank, with approval of its ethical
committee, by centrifugation on Ficoll-Hypaque (GE Healthcare,
Buckinghamshire, UK.) cushions. Monocytes/macrophages were
eliminated by adherence to plastic for at least 1 h at 37uC.
Immunoprecipitation, GST Pull-down, SDS PAGE and
Immunoblotting
These procedures were done as reported before [19]. Briefly,
cells were lysed in lysis buffer: 20 mM Tris/HCl pH=7,4,
150 mM NaCl, 5 mM EDTA containing 1% NP-40,
1 mM Na3VO4, 10 mg/ml aprotinin and leupeptin, and 1 mM
PMSF, pH 7.5, and clarified by centrifugation at 15,000 rpm for
10 min. The clarified lysates were preadsorbed on protein G-
Sepharose (GE Healthcare, Buckinghamshire, UK.) and then
incubated with Ab and protein G-Sepharose beads for 1 h.
Immune complexes were washed three times in lysis buffer and
suspended in SDS sample buffer. Proteins resolved by SDS-PAGE
were transferred electrophoretically to nitrocellulose membranes,
and immunoblotted with optimal dilutions of specific Abs,
followed by the appropriate anti-IgG-HRP conjugate. Blots were
developed by the enhanced chemiluminescence technique with
Pierce ECL Western Blotting substrate (Thermo Scientific,
Rockford IL, USA) according to the manufacturer’s instructions.
Pull-down of GST fusion proteins was done with Glutathion
sepharose beads (GE Healthcare, Buckinghamshire, UK.) in-
cubated with the clarified lysates for 2 h. The complexes were then
washed and processed as explained above for the IP. Blots were
scanned with the GS-800 Densitometer (Bio-Rad Laboratories,
CA, USA) and analyzed with the image analysis software Quantity
One (Bio-Rad Laboratories, CA, USA). Data are reported as
arbitrary units.
Luciferase Assays
Transfection of Jurkat T cells and assays for LUC activity were
performed as described previously [19,20]. Briefly, 206106 Jurkat
cells were transfected with 20 mg empty pEF vector or the
indicated plasmids, along with 3 mg of NFAT/AP-1-luc (or other
reporters) and 0.5 mg of a Renilla luciferase reporter for normal-
ization. Cells were stimulated with anti-CD3 plus anti-CD28 Abs
24 h after transfection for the last 6 h. Cells were lysed then and
processed to measure the LUC activity with the Dual Luciferase
system (Promega, CA USA) according to the manufacturer’s
instructions.
Flow Cytometry and Immunohistochemistry
Jurkat cells were stimulatd with soluble anti-CD3 plus anti-
CD28 Abs for 24 hours and were stained with Phycoerythrin (PE)-
labeled anti-CD25 or PE-IgG2b isotype control (Immunostep,
Salamanca, Spain). Data were acquired on a Gallios Flow
Cytometer instrument (Beckman Coulter, Inc. CA, USA) and
analysis was carried out with WinMDI software.
Results
LYP/CSK Binding in Human T Cells is Induced Upon T Cell
Stimulation
To verify the validity of the Pep/Csk cooperative model [6] for
LYP/CSK interaction, we first tested in HEK293 cells the
association of CSK with Arg620 and Trp620 LYP variants, in an
active or inactive state (D195A substrate trapping mutant, referred
throughout this paper as DA). In contrast with previous data for
Pep [9,21], we found that LYPW did bind CSK (Figure 1A), in
agreement with data obtained for LYP [10,14]. Thereafter, we
tested whether cell activation could affect this interaction.
Treatment of cells with pervanadate (PV), a potent PTP inhibitor,
increased the binding of CSK and LYP either active or inactive,
but the interaction of CSK with LYPW was always lower than
with LYPR (Figure 1A). To confirm these results in a cell line
more relevant to LYP function, we expressed LYP variants along
with CSK in Jurkat cells, a well-known model for the study of early
TCR signaling. In these cells, LYPW also interacted with CSK
(Figure 1B) and, as before, this interaction was increased after PV
treatment. IP of either LYP or CSK in Jurkat cells resulted in
a very low co-precipitation of the other protein in resting cells
(Figure 1C, upper panel); however, this association augmented
after PV treatment (Figure 1C, middle panel) or TCR stimulation
(Figure 1C, lower panel). Additionally, we verified that LYP/CSK
interaction between endogenous proteins was increased upon CD3
and CD28 co-stimulation in PBLs (Figure 1D). The efficiency of
stimulation in these cells was checked by Western blot with anti-
PY Ab (Figure S1). Stimulation upon CD3 cross-linking alone also
increased LYP/CSK interaction in a similar way to CD3 and
CD28 co-stimulation (Figure S2). From these data, we concluded
that, while Pep/CSK interaction is constitutive, the interaction
between LYP and CSK could be induced by cellular activation. It
is also worthy to mention the existence of a shift in the band that
Regulation of TCR Signaling by LYP/CSK Complex
PLOS ONE | www.plosone.org 2 January 2013 | Volume 8 | Issue 1 | e54569
corresponds to LYP in cells treated with PV (Figure 1A and B) that
can be most likely explained by LYP phosphorylation.
P1 and P2 LYP Motifs Bind to CSK
The previous data suggested that either Arg620 is less critical
than expected for CSK binding or CSK binds LYP through
Figure 1. LYP binds to CSK in an inducible manner. A, Total lysates (TL) of HEK293 cells transiently transfected with LYP tagged with the myc
epitope and HA-CSK, including the empty vector pEF as control, and treated or untreated with pervanadate (PV) for 5 min were subjected to
immunoprecipitation (IP) and immunoblot (IB) with the indicated antibodies. B, Lysates from Jurkat cells transfected with plasmids that express myc-
LYPR-DA or myc-LYPW-DA treated with PV for 5 minutes were subjected to IP with anti-myc Ab and then blotted with anti-HA (upper panel) to detect
CSK. Similar expression of the proteins in the assay was detected by IB in the TL. C, Lysates of Jurkat cells untreated (resting cells), treated with PV or
stimulated with anti-CD3 and anti-CD28 Abs for 5 min were subjected to IP with anti-CSK Ab, anti-LYP Ab, or an irrelevant Ab used as control, and
inmunoblotted against endogenous LYP and CSK. D, T lymphocytes obtained from peripheral blood of healthy donors were incubated for the
indicated times at 37uC with medium alone or in the presence of anti-CD3 and anti-CD28 Ab. Lysates from these cells were immunoprecipitated with
anti-CSK or an irrelevant Ab (IgG) to show specificity, and the presence of LYP and CSK in the precipitates was detected with specific Abs by IB. LYP
blot was measured by densitometry and the values obtained, shown under the blot, are expressed in arbitrary units.
doi:10.1371/journal.pone.0054569.g001
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additional PRMs. In fact, LYP, as Pep, contains two additional
motifs, the P2 motif, which shows a high similarity with the P1
motif, and the CTH motif. To discard the implication of the CTH
motif we tested the interaction of CSK with a mutant of LYP
lacking this motif (LYP-DCTH) by IP. In these assays, CSK was
precipitated by LYP-DCTH in a similar way to LYP (Figure 2A).
Furthermore, to determine which PRM binds CSK, we fused
them with GST and produced the recombinant proteins in
bacteria. Pull-down assays of Jurkat cell lysates with these fusion
proteins showed that while P1W and CTH motifs did not bind,
P1R and P2 motifs did bind to CSK (Figure 2B), the later with
lower affinity.
To define the contribution of different residues in P1 and P2
LYP motifs to CSK binding, we mutated key residues of these
motifs: Pro615, Pro618, R620W in P1 motif, and Pro695 and
Arg700 in P2 motif. We tested the association of CSK with these
mutants by co-IP assays in HEK293 cells transiently transfected.
Unlike the data reported on Pep [21], none of the point mutants
blocked completely LYP/CSK association. The single mutants
that showed a lower binding were P618A and R620W poly-
morphism (Figure 2C). As other studies indicated that residues in
the C-terminus of the P1 motif of Pep [8], equivalent to Ile626 and
Val627 in LYP, contributed to Pep/CSK association, we replaced
these aa by Ala (R-IV) and tested whether their mutation could
abolish CSK/LYP binding. Again, whereas mutation of these
residues in Pep blocked its association to CSK [8], I626A and
V627A substitutions reduced, but did not abolish, LYP/CSK
binding (Figure 2D). Therefore, based on the evidence collected so
far, we reasoned that CSK also bound to LYP through the P2
motif; and that to abolish this association, both P1 and P2 motifs
should be mutated. This hypothesis was tested by co-IP assays in
which mutation of both motifs did abolish the association of CSK
and LYP proteins in any of the combinations used, either P615A/
P618A/P695 or W-P695A (Figure 2E). Furthermore, to confirm
these data using different mutations, we replaced Arg620 and
Arg700 by Phe, based on the information provided by the ADAN
database [22], which predicts Phe as one of the aa with the lowest
affinity in that position of P1 peptide. As before, only the double
mutant completely abrogated LYP/CSK binding (Figure 2F).
Altogether, these data indicated that CSK binds to two different
motifs in LYP, P1 and P2, of which P1 showed a higher affinity.
Accordingly, the change of Arg620 by a Trp reduced but did not
abolish CSK binding.
CSK SH2 and SH3 Domains are Involved in Binding to LYP
The LYP residues that contribute to CSK binding have been
studied largely. However, less attention has been paid to the CSK
aa critical for this interaction. To address this issue, we generated
D27A and W47A CSK mutants, which interact with Arg620 and
Pro618 in LYP, respectively [23]. In addition, a careful exami-
nation of the NMR models of Ghose et al. suggested that Gln26
could form a hydrogen bond with Arg620 in LYP (Figure 3A),
which prompted us to mutate Gln26 to Ala and test its binding to
LYP. We observed that while D27A and W47A mutants blocked
the association with LYP, the Q26A mutant seems less critical for
this association (Figure 3B). Given that LYP/CSK interaction was
increased by PV treatment (Figure 1A), we asked whether the SH2
domain of CSK was involved in the interaction with LYP. To
prove this, we mutated CSK Arg107 to Met, because this residue,
conserved in SH2 domains, is critical for binding to phospho-Y in
protein ligands [24]. The R107M mutation decreased the
association of CSK with LYP in cells treated with PV, but also
in resting cells (Figure 3D). Whereas W47A mutation abolished
the interaction with LYP, as did the triple mutant D27A/W47A/
R107M; binding of CSK-D27A to LYP was increased after PV
treatment, indicating that D27A mutant still binds LYP and that
PV treatment increased this binding, (Figure 3D). Collectively,
these data showed that the SH2 domain of CSK participates in the
association with LYP, although the primary interaction is
established with the CSK SH3 domain, in which is critical the
Trp47. In addition, we tested the CSK mutants generated to study
the interaction of this kinase with LYP in functional assays in
Jurkat cells (Figure 3D). These mutants did not affect the negative
role played by CSK in the regulation of TCR signaling, suggesting
that CSK regulation of TCR signaling is not dependent on LYP
binding.
Relevance of LYP/CSK Interaction for TCR Signaling
A consequence of the LYP C1858T polymorphism is a reduction
in CSK binding that can be the cause of the alterations produced
by this variant in the immune system. To determine how this
polymorphism affects TCR signaling, and to evaluate the
importance of LYP/CSK interaction in these pathways we used
several CSK and LYP mutants that bind to each other in different
degrees. First, we carried out luciferase assays in Jurkat cells to
compare the activity of LYPR and LYPW in different promoters
relevant for T cells, such as NF-AT/AP1 sites of the IL-2
promoter, Gal4-ELK or NF-kB (Figure S3). We observed in these
assays that LYPW had a similar activity than LYPR. Next, we
observed that LYPW-P695A and LYP-F620A/F700A, which are
mutated in both P1 and P2 motifs and do not interact with CSK,
inhibited the activation of the IL-2 minimal promoter as did
LYPR and LYPW (Figure 4A). We also determined the activation
of Erk in the presence of LYPR, LYPW or LYPW-P695A
(Figure 4B) and the activation of p38 in the presence of LYPR or
LYPW (Figure 4C), obtaining a similar inhibition, in agreement
with the data obtained in the luciferase assays. Although the
inhibitory role of LYPW in these assays could have been explained
by the binding to endogenous CSK through the P2 motif, LYPW-
P695A and LYP-F620A/F700A do not bind to CSK at all,
precluding any effect of the interaction of LYP with endogenous
CSK in these assays. In addition, to address the cooperation of
LYP and CSK in TCR signaling, we expressed CSK along with
LYPR and LYPW to measure the induction of a promoter with
NF-AT/AP1 sites of IL-2 (data not shown). In both cases CSK
cooperated with LYPW as well as with LYPR, and in both cases
co-expression of CSK and LYP produced a greater inhibition than
any of the proteins alone. Likewise, when CSK-W47A, which
showed no binding to LYP, was co-expressed with LYPR and
LYPW there was an increase of the inhibition of the NF-AT/AP1
and IL-2 minimal promoter (Figure 4D and E). We also tested
whether LYP and CSK versions that do not interact to one
another could reduce the expression of CD25 in Jurkat cells. This
experiment showed that a combination of plasmids like LYPW-
P695A and CSK-W47A, are still able to reduce the induction of
this activation marker (Figure 4F). Collectively, we conclude from
these data that the cooperation of LYP and CSK proteins to
regulate TCR signaling does not require a direct interaction
between them.
LYP is Phosphorylated in Tyrosine
As PV treatment produced a shift in LYP SDS-PAGE mobility
(Figure 1A), we speculated that this shift could be due to Tyr
phosphorylation. To address this issue, a PBLs were stimulated
through CD3 and CD28 receptors, and LYP was shown to be
phosphorylated in tyrosine by Western blot (Figure 5A). Next, to
determine the kinase(s) responsible for this phosphorylation, we co-
expressed in Jurkat cells LYPR-DA with several kinases relevant
Regulation of TCR Signaling by LYP/CSK Complex
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Figure 2. P1 and P2 LYP motifs bind to CSK. A, Lysates of HEK293 cells transfected with LYP and a deletion mutant of LYP tagged with the myc
epitope that lacks the CTH PRM, tagged with the myc epitope, along with HA-CSK plasmids were immunoprecipitated and immunoblotted with the
Regulation of TCR Signaling by LYP/CSK Complex
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indicated Abs. Expression of these proteins was verified by IB in TL. B, Lysates from 36108 Jurkat cells were divided equally into five tubes and were
subjected to pull-down assays with the indicated PRMs fused to GST. The presence of CSK in the precipitates was detected by IB with CSK Ab and
GST-peptides were detected using a GST Ab. TL shows the presence of CSK in the lysate. C, Lysates of HEK293 cells transfected with different LYP
mutants in the P1 and P2 motifs, tagged with the myc epitope, along with HA-CSK were subjected to IP and IB as indicated. D, Interaction of HA-CSK
with a myc-LYP mutant in the C-terminus of the P1 motif, IV, (Ile626Ala,Val627 Ala) was verified by IB after LYP IP in transiently transfected HEK293
cells. E, Lysates of HEK293 cells transfected with HA-CSK and different mutants of LYP in the P1, the P2, or in both motifs, tagged with the myc
epitope, were immunoprecipitated and immunoblotted with the indicated Abs. F, Arg to Phe LYP mutants in P1 and P2 PRM tagged with myc were
expressed in HEK293 cells and interaction with HA-CSK was detected by immunoblot after LYP immunoprecipitation. CSK blots in panels B, C, D, E
and F were scanned and the values obtained were expressed as arbitrary units under the blot.
doi:10.1371/journal.pone.0054569.g002
Figure 3. CSK SH3 and SH2 domains are involved in the association with LYP. A, Schematic representation of the NMR structure of the Pro
rich motif P1 of Pep (orange) bound to the SH3 domain of CSK (blue) (PDB code 1JEG). P1 resid ues are numbered according to the LYP sequence
(613IPPPLPVRTPESFIVVEE630). Arg620 is involved in intermolecular polar contacts with Asp27 and Gln26 of CSK; hydrogen bonds are shown by
dashed lines. In addition, Arg620 could establish an intramolecular hydrogen bond with Ser624. B, Jurkat cells were electroporated with HA-CSK wild
type and several mutants of CSK SH3 domain along myc-LYPR as indicated. Interaction was detected by IB after LYP IP. C, Several HA-CSK mutants in
the SH3 and SH2 domains were tested for interaction with myc-LYP-RDA. Jurkat cells were left untreated or treated with PV and LYP was
immunoprecipitated from cell lysates. CSK interaction was detected by IB with specific anti-HA antibody. D, Activation of a luciferase reporter gene
driven by the IL-2 minimal promoter in Jurkat cells cotransfected with different CSK plasmids, as indicated. The insert shows the IB of the CSK proteins
expressed.
doi:10.1371/journal.pone.0054569.g003
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Figure 4. LYP/CSK interaction is not required to regulate TCR signaling. A, Activation of a luciferase reporter gene driven by the IL-2
minimal promoter in Jurkat cells co-transfected with different myc-LYP plasmids, as indicated. The insert shows the expression of the LYP proteins as
detected by IB. B, Erk activation was assayed in Jurkat cells transfected with different versions of LYP, as indicated, and stimulated with anti-CD3 Ab
Regulation of TCR Signaling by LYP/CSK Complex
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for T cells (Figure 5B). Co-expression of LCK, Fyn, and CSK lead
to LYP Tyr phosphorylation, being the highest phosphorylation
produced by LCK. To confirm that LCK was the main kinase
involved in LYP phosphorylation, we used Jurkat derived cell lines
deficient in LCK, JCam1.6, and in Zap70, P116 (Figure 5C). PV
treatment of Jurkat and P116 cells lead to similar levels of LYP Tyr
phosphorylation, while in JCam1.6 cells there was a residual
phosphorylation that can be explained by the presence of FYN or
CSK in these cells. We also detected in vitro LYP phosphorylation
by LCK (Figure 5D), further supporting LCK as a key kinase in
LYP tyrosine phosphorylation. Our analysis on LYP phosphory-
lation was followed by the identification of the tyrosines
phosphorylated. To this end, we transfected several Tyr to Phe
mutants, in a LYPR-DA inactive version, chosen based on the
phosphorylation sites predicted by Netphos [25] or Scansite [26],
and on the degree of evolutionary conservation. Co-transfection of
LCK with the LYP Tyr to Phe mutants showed that the main sites
phosphorylated by LCK were Tyr526 and Tyr536 (Figure 5E).
We also tested whether there was any difference in the
phosphorylation of LYPR and LYPW in Jurkat cells by LCK,
which in fact was similar (Figure 5F). Then, we evaluated whether
LYP phosphorylation on these residues, Tyr526 and Tyr536, was
involved in the regulation of TCR signaling. Expression of LYP
Y526F and Y536F mutants showed no effect with respect of LYPR
on the activation of the IL-2 promoter in luciferase assays
(Figure 5G), in disagreement with data published recently [14].
We also tested whether these mutants affected the interaction of
LYP with CSK, but our results showed that they are not involved
in this interaction (Figure S4),These results indicate that TCR
stimulation leads to Y-phosphorylation of LYP, and that
phosphorylation of Tyr526 and Tyr536 does not affect LYP
function during TCR signaling.
Discussion
The C1858T polymorphism of LYP plays a critical role in the
pathogenesis of several autoimmune diseases. This polymorphism
changes to a Trp the Arg620 that is essential for LYP binding to
CSK, suggesting that a change in the association between these
proteins will contribute to the generation of autoimmunity. Here,
we analyzed the association between LYP and CSK, and its
relevance to TCR signaling. Our work suggests that LYP/CSK
interaction is more complex than expected from the data reported
on Pep/Csk binding. Whereas Pep/Csk interaction is constitutive
[6], LYP binding to CSK is dynamic and is increased by cellular
activation, involving CSK SH3 and SH2 domains along with LYP
P1 and P2 motifs. Extensive mutation of critical residues in the P1
motif: Pro615, Pro618, Arg620, Ser624, Ile626, Val626 did not
abolished CSK binding to LYP, differing from the data reported
on Pep [8]. Our data also show that CSK does bind to LYPW.
Although this observation is not entirely novel, it is novel the
demonstration that this binding is mediated by the P2 motif of
LYP. Again, this is another controversial fact regarding LYP. The
study of Pep/Csk interaction showed initially that a weak in-
teraction exists on a yeast two-hybrid assay when the P1 motif is
deleted [12]. Another work reported that mutations in the P1
motif of Pep abrogated Csk binding [8]. Later on, it was found that
Pep binds to Csk after deletion of the P1motif in stable cell lines
generated with different constructs of Pep [6]. Other reports have
not detected LYPW interaction with CSK [27,28]. However, in
agreement with our data, other studies have reported that LYPW
interacts with CSK [10,14]. Particularly, the work of Fiorillo et al.
showed this interaction in vitro between recombinant proteins.
These last studies, as well as the data here presented, show that the
affinity of LYPW by CSK is lower than that of LYPR, in parallel
to the affinity of the P1 and P2 motifs, and the low affinity of the
P2 motif may be the cause of the difficulties found to detect this
interaction.
A complementary view of the association between LYP and
CSK was obtained with the study of the CSK residues critical for
this association. Thus, Trp47, in the CSK SH3 domain, is the key
CSK residue for this interaction, as the sole mutation W47A
abolished LYP-CSK interaction. Asp27 seems less critical for this
interaction because a CSK D27A mutant still binds LYP and,
more important, binding to LYP was increased after PV
treatment. Moreover, we showed the involvement of an additional
CSK residue, Gln26, which shows polar contacts with Arg620 in
LYP (Figure 3A). In addition to the SH3 domain, our data support
the implication of CSK SH2 domain in LYP/CSK association,
because the SH2 CSK mutant, R107M, reduces this interaction.
In particular, the SH2 domain appears to be responsible for the
increase observed in the association between these proteins upon
TCR engagement. The fact that the SH2 CSK mutant, R107M,
also showed a lower association to LYP in resting cells could be
due to the existence of basal LYP phosphorylation or to an
alternative mechanism of interaction, currently unknown, that
might involved the interaction with a third protein. LYP is not the
first PEST PTP in which tyrosine phosphorylation is involved in
binding to CSK, as it has been already shown that PTP-HSCF
binds to CSK SH2 domain [29].
The CSK mutants used in this study clearly affect the
association of this kinase with LYP, as we have shown throughout
this paper; however they do not differ much from CSK wild type
in the regulation of TCR signaling (Figure 3D), in contrast with
previous works, which have reported that deletion of these
domains in CSK abrogates TCR signaling [7,30,31]. It can be
argued that point mutation, in contrast to domain deletion, is
expected to produce a lower effect in the overall structure of the
protein while affecting ligand binding. In fact, another study
pointed that CSK SH3 and SH2 domains are critical for CSK to
show full kinase activity [32]; and the recent structural data on the
Src/CSK complex shows that SH3 and SH2 CSK domains are
not involved in Src recognition by CSK [33]. The role of CSK
SH2 domain in the negative regulation of TCR signaling is
controversial because despite being implicated in CSK recruit-
ment to the plasma membrane through the association with PAG/
Cbp, as judged from a flurry of biochemical data; however,
knockout mice for PAG/Cbp showed no alteration in T cell
for 5 min. Erk was immunoprecipitated from lysates of these cells and its phosphorylation was detected by IB. Expression was verified in total lysates
(TL) by IB. Phospho-ERK (P-Erk) blot was measured by densitometry and the data were expressed as arbitrary units under the blot.C, As in B, p38
activity was evaluated in Jurkat T cells stimulated with anti-CD3 and anti-CD28 Ab for 30 min by IP of HA-p38 and IB with a specific antibody for
dually phosphorylated p38. Phospho-p38 (P-p38) blot was measured by densitometry scanning and the data were expressed as arbitrary units under
the blot. D, Activation of a luciferase reporter gene driven by the NF-AT/AP1 site of IL-2 promoter in Jurkat cells co-transfected with LYPR, LYPTW, and
CSK-W47A plasmids, as indicated. Expression of LYP and CSK proteins as detected by IB is shown in the insert. E, Activation of a luciferase reporter
gene driven by the IL-2 minimal promoter in Jurkat cells transfected with LYPR, LYPW, and CSK-W47A plasmids. The insert shows the IB of LYP and
CSK proteins. R, LYPR; W, LYPW. F, Expression of CD25 in Jurkat cells transfected with the plasmids indicated was measured by flow cytometry upon
stimulation with anti-CD3 plus anti-CD28 antibodies for 24 hours. Expression of LYP and CSK proteins as detected by IB is shown in the insert.
doi:10.1371/journal.pone.0054569.g004
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activation and development [34,35]. The same was true for LIME,
another membrane adaptor related to PAG that interacts with
CSK by a similar mechanism [36].
The regulatory function of LYP on TCR signaling is well
documented. However, the consequences of the R620W SNP for
T cell function remain controversial. Initially, it was proposed that
LYPW was a gain-of-function variant of this PTP [13]. The gain of
function of LYPW has been mainly ascribed to the initial steps of
antigen signaling in T cells, being less clear at later steps, for
example IL-2 production [13,37,38,39] or T cell proliferation
[37]. On the contrary, other reports suggested that LYPW is a loss
of function variant [15,16]. In the present study, we have found
that LYPW behaves similarly to LYPR in the context of TCR
signaling. Therefore, our data support a third possibility, i.e.,
LYPW is neither a gain- nor a loss-of-function in the context of
TCR signaling. According to our results, mutations that reduced
or abolished this interaction do not affect to the capacity of these
proteins to regulate TCR signaling. Thus, a combination of
mutants like CSK-W47A and LYPW still cooperate to further
reduce TCR signaling indicating that cooperation of LYP and
CSK on TCR signaling is not based on a direct physical
interaction. In this sense, it is worthy to mention here that
removal of the CSK binding motif in PTP-PEST, another PEST
phosphatase, had no consequence for PTP-PEST regulatory role
in B cells [40]. A recent work has shown that overexpression of
CSK SH3 domain reduces TCR signaling, effect that the authors
explained by its inhibition of the interaction between endogenous
LYP and CSK. These data show that LYP inhibition of TCR
signaling does not require CSK binding, in agreement with our
data.
A change in the mobility of LYP in SDS-PAGE after PV
treatment prompted us to study LYP phosporylation. In this
respect, we have shown that LYP is phosphorylated on Tyr upon
TCR stimulation, being LCK the kinase mainly responsible for
LYP phosphorylation in T cells. Our data on LYP phosphoryla-
tion agrees with a recent report [14], although there are
discrepancies, for example in the kinetics of LYP phosphorylation,
which seems delayed in our assays, probably due to the different
cell lines used in each case. The major sites phosphorylated by
LCK appeared to be Tyr526 and Tyr536. However, it remains
elusive the role of Tyr phosphorylation for LYP function in TCR
signaling, as mutation of several Tyr to Phe, including Tyr526 and
Tyr536, did not alter the negative regulatory role of LYP in TCR
signaling.
In summary, the data collected in this report reveals that LYP/
CSK interaction is dynamic and is not based solely on a direct
binding between a PRM and an SH3 domain, being additional
mechanisms involved in this interaction. Furthermore, the in-
teraction of CSK and LYP in resting cells is increased upon TCR
engagement by a mechanism that implicates the SH2 domain of
CSK and probably LYP Tyr phosphorylation by LCK. Although
the critical role played by LYP in TCR signaling is well
documented, it is far from being clear the function of the LYP/
CSK complex as well as the consequences of the R620W
polymorphism for T cell physiology. In this regard, it will be
essential clarifying the physiological role played by LYP in the
immune system to determine how LYP function is altered by this
polymorphism.
Supporting Information
Figure S1 Activation of PBLs tested by Western blot.
Lysates corresponding to the experiment shown in Figure 1D were
immunoblotted with anti-PY Ab to show stimulation of the cells
used in this experiment.
(EPS)
Figure S2 LYP/CSK interaction by TCR stimulation. T
lymphocytes obtained from peripheral blood of healthy donors
were incubated for 15 minutes with medium alone as control (C),
in the presence of anti-CD3, or with anti-CD3 and anti-CD28
Abs. Lysates from these cells were immunoprecipitated with anti-
CSK Ab, and the presence of LYP and CSK in the precipitates
was detected with specific Abs by IB. LYP blot was measured by
densitometry and the data were expressed as arbitrary units under
the blot.
(EPS)
Figure S3 Activation of different luciferase promoters
in the presence of LYPR and LYPW. Activation of a luciferase
reporter gene driven by NF-kB (A), Gal-4-ELK (B) or the NF-AT/
AP1 sites of the IL-2 promoter (C) in Jurkat cells co-transfected
with different myc-LYPR (R) or myc-LYPW (W) plasmids, as
indicated. The insert in each panel shows the expression of the
LYP proteins as detected by IB.
(EPS)
Figure S4 Tyrosines 526 and 536 are not involved in
CSK interaction. Interaction of HA-CSK with myc-LYP
mutants, Y526F and Y536F was tested by IB after LYP IP in
transiently transfected HEK293 cells treated with PV.
(EPS)
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anti-LYPAb and immunoblotted with anti-phospho-Y Ab 4G10 to detect LYP Y-phosphorylation. After stripping, the membrane was probed with anti-
LYP Ab to verify equal loading of LYP. Zap70 phosphorylation with anti-Phospho-Y319 was tested to check activation of the cells. The blot showing
LYP Tyr phosphorylation (P-Y) was measured by densitometry and the data were expressed as arbitrary units under the blot. B, Lysates of Jurkat cells
transfected with myc-LYPR-DA and the indicated kinases were subjected to IP to detect Lyp Y-phosphorylation as in A. Expression of the kinases
transfected was detected by Western blot with anti-HA antibody, where HA was present, or with specific antibodies for the untagged kinases. C, LYP
Y-phoshophorylation was studied in different Jurkat derived cell lines deficient in LCK (JCaM1.6) and Zap70 (P116) for comparison with Jurkat
parental cells. Phosphorylation of endogenous LYP after IP was detected as aforementioned. D, In vitro phosphorylation of myc-LYP-RDA by
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